State-of-the-Art vs. Tried and Trusted - An Introduction to Bioanalytical Advances - BioPharm International

ADVERTISEMENT

State-of-the-Art vs. Tried and Trusted
An Introduction to Bioanalytical Advances


BioPharm International


Conclusion


Table 2. Application of Assay Techniques
Factors such as quality, time to market, and cost have forced an evolution of state-of-the-art analytical test methods. In addition, changes in the regulatory framework, such as PAT and biogenerics, can also drive innovation in analytical development. However, putting these techniques into routine use can be challenging. Some powerful state-of-the-art techniques are PCR and MS. (The uses for these techniques and others in protein characterization can be found in Table 2.) New techniques require evaluation and development to ensure that the data they provide is equivalent to that of more accepted and traditional methods, but nothing can replace good scientific rationale and careful experimentation and testing.

Anita Bate, Ph.D., is a team member at Eden Biopharm Ltd, D5, Stanlaw Abbey Business Centre, Dover Drive, Ellesmere Port, Cheshire, CH65 9BF, UK, 44 (0) 151.356.5632, Fax: 44 (0) 151.356.5633,

References

1. Zoon K, Gornik R. Definition of a well characterized biotechnology product. Dev Biol Stand. 1998;96:191-197.

2. US Food and Drug Administration. Guidance for Industry, PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Rockville, MD: Office of Training and Communication, Division of Drug Information, HFD-240, Center for Drug Evaluation and Research, Food and Drug Administration; September 2004. Available at: http:// http://www.fda.gov/cder/guidance/6419fnl.htm.

3. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Note for Guidance on Development Pharmaceutics. London: EMEA; 1998. (EU Directive 65/65/EEC Article 4.8, medicinal product marketing license directives.) Available at: http:// http://www.emea.eu.int/pdfs/human/qwp/015596en.pdf.

4. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Draft Guideline on Similar Biological Medicinal Products. London: EMEA; 2004. Available at: http:// http://www.emea.eu.int/pdfs/human/biosimilar/043704en.pdf.

5. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Draft Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. London: EMEA; 2005.

6. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Similar Biological Medicinal Products Containing Recombinant Human Growth Hormone (Annex to Guideline). London: EMEA; 2004.

7. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Similar Biological Medicinal Products Containing Recombinant Human Erythropoietin (Annex to Guideline). London: EMEA; 2004.

8. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Similar Biological Medicinal Products Containing Recombinant Granulocyte-Colony Stimulation (Annex to Guideline). London: EMEA; 2004.

9. EMEA Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products. Similar Biological Medicinal Products Containing Recombinant Human Insulin (Annex to Guideline). London: EMEA; 2004.

10. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975;98:503.

11. Weighart F. Quantitative PCR for the Detection of GMOs. European Commission Joint Research Centre Workshop: The Analysis of Food Samples for the Presence of Genetically Modified Organisms, Session 10. World Health Organization: 2004. Available at: http://gmotraining.jrc.it/docs/Session10.pdf.

12. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR: Real-time monitoring of DNA amplification reactions. Biotechnology. 1993;11:1026-1030.

13. Gevaert K, Vandekerckhove J. Protein identification methods in proteomics. Electrophoresis. 2000; 21(6):1145-1154.

14. Markides K, Gräslund A. (2002) Advanced information on the Nobel Prize in Chemistry 2002. Stockholm; The Royal Swedish Academy of Sciences: 2002. Available at: http://nobelprize.org/chemistry/laureates/2002/chemadv02.pdf.

15. Rivier J, McClintock R. Reverse phase high-performance liquid chromatography of insulins from different species. J Chrom. 1983;268:112-119.

16. Seamon KB. Specifications for biotechnology derived protein drugs. Curr Opin Biotech. 1998;9:319-325.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health
April 22, 2014
Novartis and GSK Trade Assets
April 22, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here